Insulin aspart
Based on 1 Customer Validation
Insulin aspart (B28Asp) is a rapid-acting h-Insulin (HY-P0035) analog. Insulin aspart induces a faster hypoglycemic effect. Insulin aspart can be used in diabetes-related research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 95%
- No. CAS: 116094-23-6
- Fòrmula: C256H381N65O79S6
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Insulin aspart (5 IU/kg; subcutaneous injection; single dose) produces sustained and stable systemic hyperinsulinemia in both male and female non-diabetic mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6−8 weeks old, streptozotocin-induced diabetic)[2]
-
Dosage:5 IU/kg
-
Administration:s.c.; once daily; 5 consecutive days
-
Result:Boosted plasma insulin levels in fed diabetic mice to 127.6 μIU/mL, with elevation persisting for only 2 h.
Caused a sharp decrease in blood glucose levels in fasted diabetic mice to 109.5 mg/dL at 1 h postinjection, indicating hypoglycemia risk.
Did not induce noticeable hepatic Akt phosphorylation.
Exhibited consistent glycemic control efficacy on Days 1, 2, and 5, with blood glucose-lowering effects comparable to oral casNP/insulin/C10 at 50 IU/kg but with a shorter duration of action.
-
Animal Model:(male, female, nondiabetic)[2]
-
Dosage:5 IU/kg
-
Administration:s.c.; single dose
-
Result:In male nondiabetic mice, reached an initial insulin level of 2,053 μIU/mL at baseline, increased modestly to 2,429 μIU/mL at 15 min, then declined to 1,500−1,650 μIU/mL over 1 to 4 h before rising slightly to 1,801 μIU/mL at 8 h.
In female nondiabetic mice, peaked at 2,506 μIU/mL at 1 h, followed by a gradual decline, yet maintained elevated levels of 1,942 μIU/mL at 8 h.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 116094-23-6
-
Appearance Liquid
-
Fòrmula C256H381N65O79S6
-
Color Colorless to off-white
-
Synonyms
B28Asp; B28-Asp-insulin; INA-X 14; Insulin X 14
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Mudaliar SR, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999 Sep;22(9):1501-6. [Content Brief]
[2]. Thamizhchelvan AM, et al. Small Intestine-Targeted Long-Acting Oral Insulin Formulation Based on Engineered Milk Protein Nanoparticles. ACS Appl Bio Mater. 2026;9(2):1083-1097. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Insulin aspart Related Classifications
HY-108767 Related Classifications
Powered by Bioz
- Insulin aspart
- 116094-23-6
- B28Asp
- B28-Asp-insulin
- INA-X 14
- Insulin X 14
- Insulin X14
- Insulin X 14
- Insulin X-14
- Insulin Receptor
- Drug Derivative
- insulin/IGF-1 receptor
- streptozotocin-induced diabetic mice
- nondiabetic mice
- diabetes mellitus
- postprandial hyperglycemia
- hypoglycemic agent
- glucose-lowering agent
- hexamerization inhibitor
- insulinotropic agent
- diabetic mice
- Inhibitor
- inhibitor
- inhibit